JPRN-UMIN000012239已完成未知
An open-label parallel group randomized controlled trial for investigating the efficacy and persistence of internet self-learning and filmed social contact for reducing stigma in the university students. - A randomized controlled trial for investigating the efficacy of internet self-learning and filmed social contact for reducing stigma in the university students.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 25years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The students who will not be university or college students one year later, the students who will not live in Japan one year later, and 3 grades or more students in the department of medicine or psychology at registration.
研究者
相似试验
尚未招募
2 期
Ayurvedic management of primary obesity - A clinical studyCTRI/2022/06/043128Dr Sarjita Tusharbhai Patel
进行中（未招募）
不适用
A randomised controlled parallel group open-label study to evaluate theefficacy and safety of intravenous ferric carboxymaltose versus no treatment inanaemic subjects with lymphoid malignancies and functional iron deficiencyreceiving chemotherapy - FER-FID-CHEMOAnaemic subjects with lymphoid malignancies and functional iron deficiencyreceiving chemotherapyMedDRA version: 14.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10002034Term: AnaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-015767-14-DEVifor (International) AG40
进行中（未招募）
不适用
A randomised controlled parallel group open-label study to evaluate theefficacy and safety of intravenous ferric carboxymaltose versus no treatment inanaemic subjects with lymphoid malignancies and functional iron deficiencyreceiving chemotherapy - FER-FID-CHEMOAnaemic subjects with lymphoid malignancies and functional iron deficiencyreceiving chemotherapyMedDRA version: 14.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10002034Term: AnaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-015767-14-ATVifor (International) AG40
进行中（未招募）
1 期
A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-restricted erythropoiesis receiving chemotherapyTreatment of anaemic subjects with multiple myeloma and iron restricted erythropoiesis receiving chemotherapy.MedDRA version: 12.0Level: LLTClassification code 10028228Term: Multiple myelomaMedDRA version: 12.0Level: LLTClassification code 10049467Term: Erythropoiesis abnormalEUCTR2009-015766-56-FRVifor Pharma Inc.40
进行中（未招募）
不适用
A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-restricted erythropoiesis receiving chemotherapyTreatment of anaemic subjects with multiple myeloma and iron restricted erythropoiesis receiving chemotherapy.MedDRA version: 13.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10049467Term: Erythropoiesis abnormalSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-015766-56-DEVifor Pharma Inc.40